Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00161837
Status:
COMPLETED
Last Update Posted:
2015-10-09
First Post:
2005-09-08
Brief Title:
Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 20032004
Sponsor:
Resilience Government Services Inc
Organization:
Resilience Government Services Inc
Study Overview
Official Title:
Single-blind Randomized Controlled Phase IIIII Study to Investigate the Immunogenicity and Safety of an Inactivated Influenza Vaccine Whole Virion Vero Cell Derived in Comparison to a Licensed Egg-derived Influenza Vaccine for Season 20032004
Status:
COMPLETED
Status Verified Date:
2006-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objectives of the study are to assess the immunogenicity and safety of the inactivated influenza vaccine whole virion Vero cell-derived at Day 21 and Day 180 after vaccination
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None